Lantheus alpha therapy, CATX director, sells $131k in stock
Lantheus alpha therapy, CATX director, sells $131k in stock
Lantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, Inc. (NASDAQ:CATX), sold shares totaling $131,219 on September 2, 2026.
The transactions involved the disposition of 42,129 shares of common stock. The shares were sold at a weighted average price of $3.1147 per share, with individual transaction prices ranging from $3.025 to $3.235. The sale price aligns closely with the current stock price of $3.13, though shares remain down 39% over the past six months and 49% below their 52-week high of $6.16.
Following these transactions, Lantheus Alpha Therapy, LLC directly holds 11,521,296 shares of Perspective Therapeutics common stock. Lantheus Alpha Therapy, LLC is an indirect wholly owned subsidiary of Lantheus Holdings, Inc., which may be deemed to have indirect beneficial ownership of these shares. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. The company maintains a strong balance sheet with more cash than debt and a current ratio of 6.61, though InvestingPro notes the stock exhibits high volatility—among 10+ additional ProTips available to subscribers.
In other recent news, Perspective Therapeutics Inc. has been the focus of several analyst evaluations. BMO Capital initiated coverage on the company with an Outperform rating and set a price target of $11. Piper Sandler, while maintaining an Overweight rating, adjusted its price target from $16 to $14, citing the company’s second-quarter 2026 earnings report. During this report, Perspective Therapeutics reaffirmed expectations for pivotal site activation for bamzireotide navoxetan around the end of 2026. Additionally, BTIG reiterated a Buy rating and maintained a $14 price target, expressing increased confidence in the company as a top pick for the second half of 2026. BTIG highlighted the company’s Pb-212 manufacturing infrastructure as a notable competitive advantage. These developments reflect ongoing interest and varied perspectives from analysts regarding Perspective Therapeutics’ future prospects.